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Abstract:We previously reported one patient with squamous cell
carcinoma of the lung that showed the long-term effect to
gefitinib with complete response. In the present report, we ex-
amine the epidermal growth factor receptor (EGFR) and K-RAS,
HER2, and B-RAF mutations in this patient to find a B-RAF
exon11 mutation, resulting in a substitution of valine by phenyl-
alanine at codon 470 (V470F) as a novel type of B-RAF mutation
in human cancers. In addition, the fluorescence in situ hybridiza-
tion analysis for EGFR showed the high polysomy status. B-RAF
is a nonreceptor serine/threonine kinase whose kinase domain has
a structure similar to other protein kinases, including EGFR
members. Of interest, the B-RAF V470F mutation corresponds to
a position similar to the EGFR G719X mutation located on the
phosphate binding (P)-loop of EGFR that clamps ATP into the
catalytic cleft. This observation suggests that gefitinib may have
an anti-cancer effect on B-RAF mutant tumors. Indeed, previous
reports demonstrated that H1666 cells harboring B-RAF G465V
mutations showed sensitivity to gefitinib, inhibiting phosphory-
lation of ERK1/2. We examined the effect of gefitinib on tran-
sient transfectants of the B-RAF mutant, but no drastic inhibition
of ERK1/2 phosphorylation that was one of the downstream
molecules of B-RAF was induced by gefitinib.
In summary, we found a novel B-RAF V470F mutation in
lung squamous cell carcinoma that showed response to gefitinib.
However, our in vitro investigation did not explain the response
observed in this particular patient. Further investigation is nec-
essary to elucidate the mechanism of tumor sensitivity to EGFR
tyrosine kinase inhibitors.
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A molecular targeting approach would enable therapeuticbenefits to be maximized while minimizing toxicity to
non-malignant cells. Epidermal growth factor receptor
(EGFR) is highly expressed in epithelial tumors including
lung cancers1 and EGFR tyrosine kinase inhibitors (TKIs),
4-anilinoquinazoline compounds, like gefitinib or erlotinib,
were introduced as EGFR-targeting anti-tumor reagents.
Rapid progress has been made in identifying factors
that determine responsiveness to EGFR-TKIs in non-small
cell lung cancer. The EGFR mutation has been reported to be
a biological predictor of responsiveness to gefitinib. These
mutations occur in the ATP binding cleft of the TK domain
in which EGFR-TKIs compete with ATP for binding.2,3 The
EGFR-associated signaling cascade consists of several mol-
ecules with known abnormalities, including EGFR, HER2,
K-RAS, and B-RAF. Interestingly, there is no coincidence
among these aberrations, suggesting that each alteration plays
a causative role in lung carcinogenesis.4
Previous studies indicate that EGFR-TKIs revealed
responsiveness in approximately 80% of EGFR mutant tu-
mors. However, no drug-sensitizing EGFR mutation was
found in the remaining 20%, which suggests that other
factors, such as increased copy number of EGFR, may cause
tumor response to the drug, but this mechanism is not fully
understood.5,6 We previously reported the case of one patient
with squamous cell carcinoma (SCC) of the lung that showed
complete response to gefitinib.7 In this study, we found a
B-RAF mutation in the patient that is assumed to be an
oncogenic mutation8 and investigated the effect of gefitinib
on HEK293T cells transfected with various types of B-RAF
mutants.
MATERIALS AND METHODS
Patients and EGFR, HER2, K-RAS, and B-RAF
Analysis
The mutation status of EGFR exon18–24, K-RAS
exon2, HER2 exon20, and B-RAF exon11 and exon15 was
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determined in three tumors (one primary tumor and two
recurrent tumors) resected from the same patient by direct
sequencing. The primers and polymerase chain reaction
(PCR) condition will be provided on request. The EGFR copy
number status was examined using fluorescence in situ hy-
bridization (FISH) in the resected specimens of tumors and
estimated using the published criteria.6,9 In addition, eight
patients showing responsiveness to gefitinib with EGFR wild-
type tumors in our previous studies and our recent cases were
examined for K-RAS, HER2, and B-RAF mutation status.5,9
The DNA sequencing was confirmed in repeating PCR reac-
tion by analyzing in both sense and antisense directions. We
obtained the permission of our institutional review board and
informed consent from each patient.
Cell Culture, Expression Constructs, and
Transfections
HEK293T cells were cultured at 37.0°C with 5% CO2
by using Dulbecco’s modified Eagle medium supplemented
with 10% heat-inactivated fetal bovine serum, 1% modified
Eagle medium non-essential amino acid solution, and 2 mM
L-glutamine. B-RAF expression vectors were constructed by
inserting full-length human B-RAF cDNA (kindly provided
by Dr. Kun-Liang Guan, University of Michigan Medical
School, MI) into pcDNA3.1-Zeo vector (Invitrogen, Carls-
bad, CA) containing C-terminal Flag epitope in frame. The
G468E, V470F, and V599E mutations were generated by
site-directed mutagenesis using a QuikChange kit (Strat-
agene, La Jolla, CA), and mutations were confirmed by
sequencing. The EGFR L858R expression vector has been
previously described.10 Transient transfection was performed
using Lipofectamine 2000 (Invitrogen). Each transfectant
was treated with 2 M gefitinib for 6 hours. Gefitinib was
provided by AstraZeneca (Waltham, MA).
Antibodies and Western Blotting
Cells were lysed with RIPA lysis solution as previously
described.10 Whole cell lysates using same amount of each
cell were separated with sodium dodecyl sulfate-PAGE,
transferred to a membrane, and detected by antibodies using
ECL plus Western blotting detection reagents (GE Healthcare
Biosciences, Piscataway, NJ). The antibodies against p44/42
Erk1/2 and phospho-p44/42 Erk1/2 (Thr202/Tyr204) were
purchased from Cell Signaling (Beverly, MA). The anti-B-
RAF antibody was obtained from BD Biosciences (San Jose,
CA).
RESULTS
Patient and Molecular Analysis
We previously reported a patient with SCC of the lung
who had experienced a long-term effect with gefitinib treat-
ment.7 In brief, a 62-year-old man with a 52.5 pack-year
smoking history was diagnosed as having clinical stage IIIB
lung SCC. He received cisplatin-based chemotherapy and
subsequently underwent surgery. After the initial surgery, the
patient developed two recurrences in the lung; additional
surgical resections were performed for each recurrence within
a 2-year period. After the patient’s third relapse in the
mediastinal lymph node, gefitinib was administered, and he
achieved complete response. Although the patient developed
acute promyelocytic leukemia after 25 months of gefitinib
administration and was subsequently treated with all-trans
retinoic acid,11 he was eventually cured; no evidence of the
recurrence of either disease has been found.
We examined the EGFR, K-RAS, HER2, and B-RAF
mutation status using direct sequencing and determined the
EGFR copy number status using FISH assay in the three
resected metachronous tumors diagnosed as recurrent dis-
ease. Mutational analysis revealed the presence of the
B-RAF codon 470 mutation at exon11, resulting in the
substitution of phenylalanine for valine (V470F) in all
three tumors resected, but not in nonmalignant lung tissue
(Figure 1). EGFR exon18–24, K-RAS exon2, and HER2
exon20 mutations were not detected. Regarding the copy
number of EGFR, the FISH analysis showed high poly-
somy status. We also examined the B-RAF mutation status
in our additional eight patients with responsiveness to
gefitinib with EGFR wild-type status, but no B-RAF
exon11 or exon15 mutation was detected.
Effect of Gefitinib on B-RAF or EGFR Mutant
Transfectants
The effect of gefitinib on phosphorylation of ERK1/2
was examined in HEK293T cells transiently transfected with
EGFR L858R, B-RAF wild-type, G468E, V470F, or V599E
mutant expression vector. B-RAF V470F transfectant exhib-
ited an increased level of ERK1/2 phosphorylation, suggest-
ing its oncogenic role (not stronger than V599E transfectant),
but it did not show inhibition of ERK1/2 phosphorylation at
2 M gefitinib. By contrast, phosphorylation of ERK1/2 in
EGFR L858R transient transfectant was inhibited at the same
drug concentration, suggesting that gefitinib might not inhibit
the B-RAF kinase activity and its downstream pathway in
B-RAF wild or mutant cells (Figure 2). We repeated this
experiment twice independent from transfection, and the
results were the same.
DISCUSSION
B-RAF is a nonreceptor serine/threonine kinase located
downstream of EGFR-RAS, which activates MEK-ERK. Its
mutation has been found in various human cancers.8 Most
mutant B-RAF proteins in cancer have increased kinase
activity, and the B-RAF V599E mutation is one of the most
FIGURE 1. Sequence electropherogram of heterozygous
point mutation. *EGFR codon 470 (V470F, GTC to TTC).
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active mutants, producing a 500-fold activated protein versus
the B-RAF wild-type.12,13 The kinase domain of B-RAF has
a structure similar to that of other kinases, including EGFR,
and most of its mutation in human cancers is also located in
the phosphate-binding loop or activation loop, as seen in
some of the EGFR mutations. However, the rate of B-RAF
mutation is less than 3% in lung cancers.4,14 The B-RAF
V470F mutation, which is a novel mutation in all kinds of
human cancers, is located in the phosphate-binding loop of
B-RAF. Of interest, the EGFR G719X mutation sensitizing to
EGFR-TKIs is also in the phosphate-binding loop, especially
in the glycine-rich (GXGXXG) motif that clamps ATP into
catalytic cleft (Figure 3).3,4,13 Whereas the B-RAF V470F
mutation was not really analogous to the EGFR G719X
mutation, which occurs directly in the GXGXXG motif, these
facts suggest that gefitinib may have an inhibitory effect on
the kinase activity of B-RAF, causing an anti-tumor effect, if
the affinity of B-RAF kinase portion to ATP and to its
competitive inhibitor gefitinib may be altered because of the
B-RAF mutation, although gefitinib is originally designed to
selectively inhibit wild-type EGFR-TK activity. Indeed, the
H1666 cell line harboring B-RAF G465V (located in the
phosphate-binding loop) mutation and EGFR wild-type
showed moderate response to gefitinib with inhibition of
ERK1/2 phosphorylation at 1 M and IC50 at 2 M, despite
a high IC50 value compared with EGFR drug-sensitizing
mutant cell lines.3,15 However, our in vitro investigation using
transient B-RAF G468E, V470F, or V599E transfectant dem-
onstrates that gefitinib did not inhibit the phosphorylation of
ERK1/2 at a concentration of 2 M. By contrast, phosphor-
ylation of ERK1/2 in the EGFR L858R transient transfectant
was inhibited at the same drug concentration. Our study
suggests that there is no strong relationship between B-RAF
mutation status and gefitinib response in an in vitro system.
Whereas the long-term effect of gefitinib in our patient may
be the result of other mechanisms, including the increased
EGFR copy number, the fact that the mutant B-RAF caused
activation of the MEK-ERK cascade for proliferation, regard-
less of the blockage of EGFR activation by gefitinib, may
explain how the B-RAF mutant protein could play a critical
role in tumor response to gefitinib.
In conclusion, we had one patient with B-RAF V470F-
mutant SCC of the lung that showed complete response to
gefitinib. However, our investigation using transient B-RAF
mutant transfection of HEK293T cells did not support our
finding in this particular patient. Further investigation is
necessary to determine tumor sensitivity to EGFR-TKIs and
to establish individual therapy for patients with non-small cell
lung cancer.
Note
The original B-RAF sequence was missing a codon
(three nucleotides) in the region encoding for the amino acids
31 and 32. To avoid confusion with original published data,
we use the original, if incorrect, numbering.13
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